Human heart-type fatty acid-binding protein for on-site diagnosis of early acute myocardial infarction

Liao, Jun; Chan, Cangel Pui-yee; Cheung, Yiu-chi; Lu, Jianhua; Luo, Yi; Cautherley, George W.H.; Glatz, Jan F. C.; Renneberg, Reinhard

doi:10.1016/j.ijcard.2008.01.049

Cited by 40 publications

(28 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The CardioDetect specificity was elevated and higher than in other studies, presumably because patients with renal impairment or skeletal muscle injury who are at risk of false positive h-FABP were not included. 11,21,38 Unlike other studies that reported high sensitivity of h-FABP for early detection of MI, we found that the test sensitivity was too low to rule out patients with a diagnosis of ACS and NSTEMI. 19,20 This result was not due to poorly collected samples or an inadequately performed test.…”

Section: Discussioncontrasting

confidence: 98%

“…18 Some studies have shown that CardioDetect is a reliable point-of-care test for the early diagnosis of acute myocardial infarction (AMI). [19][20][21] However, these studies were done in a population with STEMI and considerable myocardial damage. [19][20][21][22] Ischemia-modified albumin (IMA) is another new biologic marker of ACS.…”

mentioning

confidence: 99%

“…[19][20][21] However, these studies were done in a population with STEMI and considerable myocardial damage. [19][20][21][22] Ischemia-modified albumin (IMA) is another new biologic marker of ACS. Myocardial ischemia changes the structure of the N-terminus of serum albumin such that it reduces its binding capacity for transitional metals such as cobalt.…”

mentioning

confidence: 99%

See 2 more Smart Citations

Clinical Assessment of Ischemia‐modified Albumin and Heart Fatty Acid–binding Protein in the Early Diagnosis of Non‐ST‐elevation Acute Coronary Syndrome in the Emergency Department

Charpentier

Ducassé

Cournot

et al. 2010

Academic Emergency Medicine

View full text Add to dashboard Cite

Objectives: Heart fatty acid-binding protein (h-FABP) and ischemia-modified albumin (IMA) have recently been evaluated, but to the best of our knowledge, no study has reported an analysis of these two markers for the detection of early myocardial infarction and myocardial ischemia in a large cohort of consecutive patients presenting to an emergency department (ED). This study evaluates the diagnostic accuracy and the clinical utility of h-FABP and IMA for non-ST-segment elevation acute coronary syndrome (ACS) diagnosis in the first hour of management in an ED.Methods: In a prospective 11-month study, 677 patients admitted to the ED with chest pain and suspected non-ST-segment elevation ACS were enrolled. On presentation, blood samples were obtained for the measurement of the biomarkers h-FABP (immunodetection with CardioDetect) and IMA (albumin cobalt-binding test). Two physicians, blinded to the results of the markers, independently categorized patients as having or not having non-ST-segment elevation ACS.Results: Of the 677 patients who were prospectively recruited, non-ST-segment elevation ACS was diagnosed in 185 (27.3%). While IMA was not predictive of the ACS diagnosis (odds ratio [OR] = 1.23; 95% CI = 0.87 to 1.81), h-FABP was predictive of ACS diagnosis (OR = 4.65; 95% CI = 2.39 to 9.04) with specificity at 96.8% (95% CI = 95.4% to 98.1%) and sensitivity at 13.5% (95% CI = 10.9% to 16.1%). However, h-FABP did not add significant additional information to a predictive model that included the usual diagnostic tools for non-ST-elevation ACS management (p = 0.40). Conclusions:In this study on a large cohort of patients admitted to an ED for chest pain, IMA and h-FABP did not provide valuable information for ACS diagnosis.

show abstract

Section: Discussioncontrasting

confidence: 98%

mentioning

confidence: 99%

See 1 more Smart Citation

Clinical Assessment of Ischemia‐modified Albumin and Heart Fatty Acid–binding Protein in the Early Diagnosis of Non‐ST‐elevation Acute Coronary Syndrome in the Emergency Department

Charpentier

Ducassé

Cournot

et al. 2010

Academic Emergency Medicine

View full text Add to dashboard Cite

show abstract

“…It is a low molecular weight protein, found in the cytosol, and it has been more recently developed as cardiac biomarker [9,10,11]. It can be detected as soon as one hour after onset of ischemia and it can be seen as the earliest plasma marker available [12].…”

Section: Discussionmentioning

confidence: 99%

The use of biomarkers in detecting subclinical cardiotoxicity in doxorubicin-based treatment for paediatric patients with acute lymphoblastic leukaemia

Radu

Beldiman

Ghiorghiu

et al. 2017

Revista Romana De Medicina De Laborator

View full text Add to dashboard Cite

show abstract

“…27 A point-of-care test that uses hFABP has been developed for the diagnosis of MI in nonsurgical patients with purportedly superior sensitivity and specificity than cTnI. [28][29][30] A point-of-care test for the perioperative setting has the potential to have an effect on timeefficient risk stratification and management after cardiac surgery. Earliest identification of patients with clinically relevant myocardial injury could enable clinicians to identify patients in need of further diagnostic or therapeutic procedures to reduce loss of myocardial mass or performance.…”

Section: Why Do We Need Another Myocardial Injury Biomarker?mentioning

confidence: 99%

Heart-Type Fatty Acid Binding Protein Is an Independent Predictor of Death and Ventricular Dysfunction After Coronary Artery Bypass Graft Surgery

&NA;

2011

Survey of Anesthesiology

View full text Add to dashboard Cite

show abstract

Human heart-type fatty acid-binding protein for on-site diagnosis of early acute myocardial infarction

Cited by 40 publications

References 7 publications

Clinical Assessment of Ischemia‐modified Albumin and Heart Fatty Acid–binding Protein in the Early Diagnosis of Non‐ST‐elevation Acute Coronary Syndrome in the Emergency Department

Clinical Assessment of Ischemia‐modified Albumin and Heart Fatty Acid–binding Protein in the Early Diagnosis of Non‐ST‐elevation Acute Coronary Syndrome in the Emergency Department

The use of biomarkers in detecting subclinical cardiotoxicity in doxorubicin-based treatment for paediatric patients with acute lymphoblastic leukaemia

Heart-Type Fatty Acid Binding Protein Is an Independent Predictor of Death and Ventricular Dysfunction After Coronary Artery Bypass Graft Surgery

Contact Info

Product

Resources

About